Search

Your search keyword '"Dombret, H."' showing total 986 results
Start Over Author "Dombret, H."
986 results on '"Dombret, H."'

101. Étude clinique, histologique et moléculaire des lymphomes/leucémies lymphoblastiques de localisation cutanéomuqueuse : cohorte multicentrique de 24 cas

Author

Bontoux, C., primary, De Masson, A., additional, Boccara, O., additional, Fraitag, S., additional, Bodemer, C., additional, Dereure, O., additional, Szablewski, V., additional, Thevenin, C., additional, Boulinguez, S., additional, Lamant, L., additional, Viraben, R., additional, Ortonne, N., additional, Oro, S., additional, Beckerich, F., additional, Grange, F., additional, Durlach, A., additional, Amatore, F., additional, Boissel, N., additional, Dombret, H., additional, Bagot, M., additional, and Battistella, M., additional

Published
2018
Full Text
View/download PDF

102. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

Author

Doehner, H, Dolnik, A, Tang, L, Seymour, JF, Minden, MD, Stone, RM, Bernal del Castillo, T, Al-Ali, HK, Santini, V, Vyas, P, Beach, CL, MacBeth, KJ, Skikne, BS, Songer, S, Tu, N, Bullinger, L, Dombret, H, Doehner, H, Dolnik, A, Tang, L, Seymour, JF, Minden, MD, Stone, RM, Bernal del Castillo, T, Al-Ali, HK, Santini, V, Vyas, P, Beach, CL, MacBeth, KJ, Skikne, BS, Songer, S, Tu, N, Bullinger, L, and Dombret, H

Abstract

Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-001 study were evaluated at entry for cytogenetic abnormalities, and a subgroup of patients was assessed for gene mutations. Patients received azacitidine 75 mg/m2/day x7 days (n = 240) or conventional care regimens (CCR; n = 245): intensive chemotherapy, low-dose cytarabine, or best supportive care only. Overall survival (OS) was assessed for patients with common (occurring in ≥10% of patients) cytogenetic abnormalities and karyotypes, and for patients with recurring gene mutations. There was a significant OS improvement with azacitidine vs CCR for patients with European LeukemiaNet-defined Adverse karyotype (HR 0.71 [95%CI 0.51-0.99]; P = 0.046). Azacitidine-treated patients with -5/5q-, -7/7q-, or 17p abnormalities, or with monosomal or complex karyotypes, had a 31-46% reduced risk of death vs CCR. The most frequent gene mutations were DNMT3A (27%), TET2 (25%), IDH2 (23% [R140, 15%; R172, 8%]), and TP53 (21%). Compared with wild-type, OS was significantly reduced among CCR-treated patients with TP53 or NRAS mutations and azacitidine-treated patients with FLT3 or TET2 mutations. Azacitidine may be a preferred treatment for older patients with AML with Adverse-risk cytogenetics, particularly those with chromosome 5, 7, and/or 17 abnormalities and complex or monosomal karyotypes. The influence of gene mutations in azacitidine-treated patients warrants further study.

Published
2018

103. QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)

Author

Schlenk, R., primary, Dombret, H., additional, Amadori, S., additional, Montesinos, P., additional, Levis, M., additional, Sekeres, M.A., additional, Cortes, J., additional, Perl, A., additional, Zernovak, O., additional, Mires, D., additional, Ge, N., additional, Zhang, H., additional, Hanyok, J., additional, Macintyre, S., additional, Gökmen, S., additional, Kobayashi, K., additional, and Erba, H., additional

Published
2017
Full Text
View/download PDF

104. TCRα rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome

Author

Villarese, P, primary, Lours, C, additional, Trinquand, A, additional, Le Noir, S, additional, Belhocine, M, additional, Lhermitte, L, additional, Cieslak, A, additional, Tesio, M, additional, Petit, A, additional, LeLorch, M, additional, Spicuglia, S, additional, Ifrah, N, additional, Dombret, H, additional, Langerak, A W, additional, Boissel, N, additional, Macintyre, E, additional, and Asnafi, V, additional

Published
2017
Full Text
View/download PDF

105. Azacitidine Versus Conventional Care Regimens (CCR) in Elderly Patients (≥75 Years) with Acute Myeloid Leukemia (AML) in the AZA-AML-001 Study

Author

Seymour, J.F., primary, Buckstein, R., additional, Santini, V., additional, Döhner, H., additional, Stone, R.M., additional, Minden, M.D., additional, Kuo, C.Y., additional, Ben-Yehuda, D., additional, Bargay, J., additional, Songer, S., additional, Weaver, J., additional, Beach, C.L., additional, and Dombret, H., additional

Published
2017
Full Text
View/download PDF

108. Azacitidine Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes

Author

Döhner, H., primary, Vyas, P., additional, Seymour, J.F., additional, Santini, V., additional, Stone, R.M., additional, Minden, M.D., additional, Al-Ali, H.K., additional, del Castillo, T. Bernal, additional, Morrill, J., additional, Songer, S., additional, Weaver, J., additional, Skikne, B.S., additional, Beach, C.L., additional, and Dombret, H., additional

Published
2017
Full Text
View/download PDF

109. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Author

Döhner, H. (Hartmut), Estey, E.H. (Elihu), Grimwade, D. (David), Amadori, S. (Sergio), Appelbaum, F.R. (Frederick), Büchner, T. (Thomas), Dombret, H. (Hervé), Ebert, B.L. (Benjamin L.), Fenaux, P. (Pierre), Larson, R.A. (Richard), Levine, R. (Ross), Lo-Coco, F. (Francesco), Naoe, T. (Tomoki), Niederwieser, D. (Dietger), Ossenkoppele, G.J. (Gert), Sanz, M.A. (Miguel Angel), Sierra, J. (Jorge), Tallman, M.S. (Martin), Tien, H.-F. (Hwei-Fang), Wei, A.H. (Andrew H.), Löwenberg, B. (Bob), Bloomfield, C.D. (Clara), Döhner, H. (Hartmut), Estey, E.H. (Elihu), Grimwade, D. (David), Amadori, S. (Sergio), Appelbaum, F.R. (Frederick), Büchner, T. (Thomas), Dombret, H. (Hervé), Ebert, B.L. (Benjamin L.), Fenaux, P. (Pierre), Larson, R.A. (Richard), Levine, R. (Ross), Lo-Coco, F. (Francesco), Naoe, T. (Tomoki), Niederwieser, D. (Dietger), Ossenkoppele, G.J. (Gert), Sanz, M.A. (Miguel Angel), Sierra, J. (Jorge), Tallman, M.S. (Martin), Tien, H.-F. (Hwei-Fang), Wei, A.H. (Andrew H.), Löwenberg, B. (Bob), and Bloomfield, C.D. (Clara)

Abstract

The first edition of the European Leuke-miaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.

Published
2017
Full Text
View/download PDF

110. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Author

Seymour, JF, Doehner, H, Butrym, A, Wierzbowska, A, Selleslag, D, Jang, JH, Kumar, R, Cavenagh, J, Schuh, AC, Candoni, A, Recher, C, Sandhu, I, del Castillo, TB, Al-Ali, HK, Falantes, J, Stone, RM, Minden, MD, Weaver, J, Songer, S, Beach, CL, Dombret, H, Seymour, JF, Doehner, H, Butrym, A, Wierzbowska, A, Selleslag, D, Jang, JH, Kumar, R, Cavenagh, J, Schuh, AC, Candoni, A, Recher, C, Sandhu, I, del Castillo, TB, Al-Ali, HK, Falantes, J, Stone, RM, Minden, MD, Weaver, J, Songer, S, Beach, CL, and Dombret, H

Abstract

BACKGROUND: Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading to poor response and prognosis. More than one-half of all older (≥65 years) patients in the phase 3 AZA-AML-001 trial had newly diagnosed AML-MRC. METHODS: We compared clinical outcomes for patients with AML-MRC treated with azacitidine or conventional care regimens (CCR; induction chemotherapy, low-dose cytarabine, or supportive care only) overall and within patient subgroups defined by cytogenetic risk (intermediate or poor) and age (65-74 years or ≥75 years). The same analyses were used to compare azacitidine with low-dose cytarabine in patients who had been preselected to low-dose cytarabine before they were randomized to receive azacitidine or CCR (ie, low-dose cytarabine). RESULTS: Median overall survival was significantly prolonged with azacitidine (n = 129) versus CCR (n = 133): 8.9 versus 4.9 months (hazard ratio 0.74, [95%CI 0.57, 0.97]). Among patients with intermediate-risk cytogenetics, median overall survival with azacitidine was 16.4 months, and with CCR was 8.9 months (hazard ratio 0.73 [95%CI 0.48, 1.10]). Median overall survival was significantly improved for patients ages 65-74 years treated with azacitidine compared with those who received CCR (14.2 versus 7.3 months, respectively; hazard ratio 0.64 [95%CI 0.42, 0.97]). Within the subgroup of patients preselected to low-dose cytarabine before randomization, median overall survival with azacitidine was 9.5 months versus 4.6 months with low-dose cytarabine (hazard ratio 0.77 [95%CI 0.55, 1.09]). Within the low-dose cytarabine preselection group, patients with intermediate-risk cytogenetics who received azacitidine had a median overall survival of 14.1 months versus 6.4 months with low-dose cytarabine, and patients aged 65-74 years had median surviv

Published
2017

111. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Author

Pleyer, L, Doehner, H, Dombret, H, Seymour, JF, Schuh, AC, Beach, CL, Swern, AS, Burgstaller, S, Stauder, R, Girschikofsky, M, Sill, H, Schlick, K, Thaler, J, Halter, B, Spandl, SM, Zebisch, A, Pichler, A, Pfeilstoecker, M, Autzinger, EM, Lang, A, Geissler, K, Voskova, D, Sperr, WR, Hojas, S, Rogulj, IM, Andel, J, Greil, R, Pleyer, L, Doehner, H, Dombret, H, Seymour, JF, Schuh, AC, Beach, CL, Swern, AS, Burgstaller, S, Stauder, R, Girschikofsky, M, Sill, H, Schlick, K, Thaler, J, Halter, B, Spandl, SM, Zebisch, A, Pichler, A, Pfeilstoecker, M, Autzinger, EM, Lang, A, Geissler, K, Voskova, D, Sperr, WR, Hojas, S, Rogulj, IM, Andel, J, and Greil, R

Abstract

We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow (BM) blasts and white blood cell (WBC) count ≤15 G/L, treated with front-line azacitidine versus conventional care regimens within a phase 3 clinical trial (AZA-AML-001; NCT01074047; registered: February 2010). As results obtained in clinical trials are facing increased pressure to be confirmed by real-world data, we aimed to test whether data obtained in the AZA-AML-001 trial accurately represent observations made in routine clinical practice by analysing additional AML patients treated with azacitidine front-line within the Austrian Azacitidine Registry (AAR; NCT01595295; registered: May 2012) and directly comparing patient-level data of both cohorts. We assessed the efficacy of front-line azacitidine in a total of 407 patients with newly-diagnosed AML. Firstly, we compared data from AML patients with WBC ≤ 15 G/L and >30% BM blasts included within the AZA-AML-001 trial treated with azacitidine ("AML-001" cohort; n = 214) with AAR patients meeting the same inclusion criteria ("AAR (001-like)" cohort; n = 95). The current analysis thus represents a new sub-analysis of the AML-001 trial, which is directly compared with a new sub-analysis of the AAR. Baseline characteristics, azacitidine application, response rates and OS were comparable between all patient cohorts within the trial or registry setting. Median OS was 9.9 versus 10.8 months (p = 0.616) for "AML-001" versus "AAR (001-like)" cohorts, respectively. Secondly, we pooled data from both cohorts (n = 309) and assessed the outcome. Median OS of the pooled cohorts was 10.3 (95% confidence interval: 8.7, 12.6) months, and the one-year survival rate was 45.8%. Thirdly, we compared data from AAR patients meeting AZA-AML-001 trial inclusion criteria (n = 95) versus all AAR patients with World Health Organization (WHO)-defined AML ("AAR (WHO-AML)" cohort; n = 193)

Published
2017

112. Developing a European network for adult ALL

Author

Gokbuget, N, Bassan, R, Dekker, A, Dombret, H, Foa, Roberto, Ifrah, N, Kovacsovics, T, Labar, B, Mandelli, Franco, Meloni, Giovanna, Ribera, Jm, Smedmyr, B, Vernant, Jp, Walewski, J, Willemze, R, Hoelzer, D, and EUROPEAN WORKING GROUP FOR ADULTS ALL EWALL

Subjects
Adult, Male, Oncology, medicine.medical_specialty, International Cooperation, medicine.medical_treatment, MEDLINE, Hematopoietic stem cell transplantation, Medical Oncology, Precursor Cell Lymphoblastic Leukemia Lymphoma, Sex Factors, Meta-Analysis as Topic, Sex factors, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Prospective Studies, Prospective cohort study, Aged, Information Services, Clinical Trials as Topic, Hematology, Adult all, business.industry, Research, Hematopoietic Stem Cell Transplantation, Middle Aged, Models, Theoretical, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Europe, Female, business
Published
2004
Full Text
View/download PDF

113. 028 - Clinical aspects and outcome of lymphoblastic leukemia/lymphoma with cutaneous involvement

Author

Bontoux, C., De Masson, A., Boccara, O., Bodemer, C., Fraitag, S., Balme, B., Franck, N., Carlotti, A., Comoz, F., Verneuil, L., Brasme, J-F., Duplan, M., Croué, A., Templier, I., Beltraminelli, H., Dereure, O., Szablewski, V., Thevenin, C., Boulinguez, S., Viraben, R., Tournier, E., Lamant, L., Ortonne, N., Ingen-Housz-Oro, S., Beckerich, F., Grange, F., Durlach, A., Amatore, F., Frouin, E., McIntyre, E., Asnafi, V., Kim, R., Clappier, E., Soulier, J., Boissel, N., Dombret, H., Bagot, M., and Battistella, M.

Published
2019
Full Text
View/download PDF

114. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL

Author

Rousselot, P, Coudé, M, Gokbuget, N, Gambacorti Passerini, C, Hayette, S, Cayuela, J, Huguet, F, Leguay, T, Chevallier, P, Salanoubat, C, Bonmati, C, Alexis, M, Hunault, M, Glaisner, S, Agape, P, Berthou, C, Jourdan, E, Fernandes, J, Sutton, L, Banos, A, Reman, O, Lioure, B, Thomas, X, Ifrah, N, Lafage-Pochitaloff, M, Bornand, A, Morisset, L, Robin, V, Pfeifer, H, Delannoy, A, Ribera, J, Bassan, R, Delord, M, Hoelzer, D, Dombret, H, Ottmann, O, Rousselot, P, Coudé, M, Gokbuget, N, Gambacorti Passerini, C, Hayette, S, Cayuela, J, Huguet, F, Leguay, T, Chevallier, P, Salanoubat, C, Bonmati, C, Alexis, M, Hunault, M, Glaisner, S, Agape, P, Berthou, C, Jourdan, E, Fernandes, J, Sutton, L, Banos, A, Reman, O, Lioure, B, Thomas, X, Ifrah, N, Lafage-Pochitaloff, M, Bornand, A, Morisset, L, Robin, V, Pfeifer, H, Delannoy, A, Ribera, J, Bassan, R, Delord, M, Hoelzer, D, Dombret, H, and Ottmann, O

Abstract

Prognosis of Philadelphia-positive (Ph1) acutelymphoblastic leukemia (ALL) in the elderly has improved during the imatinib era. We investigated dasatinib, another potent tyrosine kinase inhibitor, in combination with low-intensity chemotherapy. Patients older than age 55 years were included in the European Working Group on Adult ALL(EWALL) study number 01 for Ph+ ALL (EWALL-PH-01 international study) and were treated with dasatinib 140 mg/day (100 mg/day over 70 years) with intrathecal chemotherapy, vincristine, and dexamethasone during induction. Patients in complete remission continued consolidation with dasatinib, sequentially with cytarabine, asparaginase, and methotrexate for 6 months. Maintenance therapy was dasatinib and vincristine/dexamethasone reinductions for 18months followed by dasatinib until relapse or death. Seventy-one patients with amedian age of 69 years were enrolled; 77% had a high comorbidity score.Complete remission ratewas 96% and 65% of patients achieved a3-logreduction inBCR-ABL1transcript levelsduringconsolidation.Only7patientsunderwent allogeneic hematopoietic stemcell transplantation. At 5 years, overall survivalwas 36% and up to 45% taking into account deaths unrelated to disease or treatment as competitors. Thirty-six patients relapsed, 24were tested formutation bySanger sequencing, and 75%were T315I-positive.BCR-ABL1T315Iwastested by allele-specific oligonucleotide reverse transcription-quantitative polymerase chain reaction in 43 patients and detection was associated with short-term relapses. Ten patients (23%) were positive before any therapy and 8 relapsed, all with this mutation. In conclusion, dasatinib combined with low-intensity chemotherapy was well-tolerated and gave long-term survival in 36% of elderly patients with Ph+ ALL. Monitoring of BCRABL1T315I from diagnosis identified patientswith at high risk of early relapse and may help to personalize therapy.

Published
2016

115. Phase 3 study of quizartinib (AC220) monotherapy vs salvage chemotherapy (SC) in patients (pts) with FLT3-ITD+ acute myeloid leukemia (AML) refractory to or relapsed (R/R) after 1st-line treatment with or without hematopoietic stem cell transplant (HSCT) consolidation: the QuANTUM-R study

Author

Cortes, J., primary, Gammon, G., additional, Khaled, S., additional, Martinelli, G., additional, Kramer, A., additional, Steffen, B., additional, Hogge, D., additional, Jonas, B.A., additional, Dombret, H., additional, and Perl, A., additional

Published
2016
Full Text
View/download PDF

116. Copy-number analysis identified new prognostic marker in acute myeloid leukemia

Author

Nibourel, O, primary, Guihard, S, additional, Roumier, C, additional, Pottier, N, additional, Terre, C, additional, Paquet, A, additional, Peyrouze, P, additional, Geffroy, S, additional, Quentin, S, additional, Alberdi, A, additional, Abdelali, R B, additional, Renneville, A, additional, Demay, C, additional, Celli-Lebras, K, additional, Barbry, P, additional, Quesnel, B, additional, Castaigne, S, additional, Dombret, H, additional, Soulier, J, additional, Preudhomme, C, additional, and Cheok, M H, additional

Published
2016
Full Text
View/download PDF

117. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

Author

Gokbuget, N., primary, Dombret, H., additional, Ribera, J.-M., additional, Fielding, A. K., additional, Advani, A., additional, Bassan, R., additional, Chia, V., additional, Doubek, M., additional, Giebel, S., additional, Hoelzer, D., additional, Ifrah, N., additional, Katz, A., additional, Kelsh, M., additional, Martinelli, G., additional, Morgades, M., additional, OBrien, S., additional, Rowe, J. M., additional, Stieglmaier, J., additional, Wadleigh, M., additional, and Kantarjian, H., additional

Published
2016
Full Text
View/download PDF

118. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study

Author

Bond, J., primary, Marchand, T., additional, Touzart, A., additional, Cieslak, A., additional, Trinquand, A., additional, Sutton, L., additional, Radford-Weiss, I., additional, Lhermitte, L., additional, Spicuglia, S., additional, Dombret, H., additional, Macintyre, E., additional, Ifrah, N., additional, Hamel, J.-F., additional, and Asnafi, V., additional

Published
2016
Full Text
View/download PDF

119. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis

Author

Gupta, V, Richards, S, Rowe, J, Büchner, T, Hiddemann, W, Sauerland, C, Amadori, S, Rondelli, R, Testi, Am, Attal, M, Jourdan, E, Reiffers, J, Howman, A, Patel, S, Jacobs, P, Lee, S, Brunet, S, Sierra, J, Alonzo, T, Aplenc, R, Sung, L, Cutler, C, Sun, Z, Tallman, M, Ljungman, P, Labar, B, Willemze, R, Suciu, S, Collette, S, Dombret, H, Thomas, X, Ifrah, N, Hunault-Berger, M, Mandelli, F, Vignetti, M, Tsimberidou, Am, Pagnano, K, da Souza CA, Miranda, Ec, Diaz de Heredia, C, Ortega, Jj, Cornelissen, Jj, van der Holt, B, Oh, H, Takeuchi, J, Kaizer, H, Björkholm, M, Rosenborg, A, Keating, M, Zander, A, Fielding, A, Goldstone, A, Moorman, Av, Bassan, R, Ravindranath, Y, Weinstein, H, Oriol, A, Ribera, Jm, Powles, R, Appelbaum, F, Baker, Luigi, Coltman, C, Crowley, J, Kopecky, K, Messner, H, Akan, H, Beksac, M, Hills, R, Buck, G, Davies, K, Elphinstone, T, Evans, V, Gettins, L, Gregory, C, James, S, Mackinnon, L, Mchugh, T, Morris, P, Wade, R, and Wheatley, K.

Subjects
Oncology, Homologous, Adult, medicine.medical_specialty, Adolescent, Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents, Child, Hematopoietic Stem Cell Transplantation, Humans, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Randomized Controlled Trials as Topic, Transplantation, Autologous, Transplantation, Homologous, Young Adult, Hematology, Biochemistry, Cell Biology, Immunology, medicine.medical_treatment, Hematopoietic stem cell transplantation, law.invention, Randomized controlled trial, law, Acute lymphocytic leukemia, Internal medicine, 80 and over, Medicine, Young adult, Chemotherapy, Transplantation, Lymphoid Neoplasia, business.industry, Absolute risk reduction, medicine.disease, Surgery, Adult Acute Lymphoblastic Leukemia, business, Autologous
Abstract

Hematopoietic cell transplantation (HCT) and prolonged chemotherapy are standard postremission strategies for adult acute lymphoblastic leukemia in first complete remission, but the optimal strategy remains controversial. There are no randomized trials of allogeneic HCT. In the present study, updated individual patient data were collected and analyzed from studies with information on availability of matched sibling donor (used to mimic randomization) and from randomized trials of autograft versus chemotherapy. Data from 13 studies including 2962 patients, excluding Philadelphia chromosome–positive patients, showed a survival benefit for having a matched sibling donor for patients < 35 years of age (OR = 0.79; 95% CI, 0.70-0.90, P = .0003) but not for those ≥ 35 years of age (OR = 1.01; 95% CI, 0.85-1.19, P = .9; heterogeneity P = .03) because of the higher absolute risk of nonrelapse mortality for older patients. No differences were seen by risk group. There was a trend toward inferior survival for autograft versus chemotherapy (OR = 1.18; 95% CI, 0.99-1.41; P = .06). No beneficial effect of autografting was seen compared with chemotherapy in this analysis. We conclude that matched sibling donor myeloablative HCT improves survival only for younger patients, with an absolute benefit of approximately 10% at 5 years. Improved chemotherapy outcomes and reduced nonrelapse mortality associated with allogeneic HCT may change the relative effects of these treatments in the future.

Published
2013

120. Receptor kinase profiles identify a rationale for multi-target kinase inhibition in immature T-ALL

Author

Lhermitte, L., R.B., Abdelali, Villarese, P., Bedajoui, N., Guillemot, V., Trinquand, A., Libura, M., Bedin, A.S., Petit, A., Dombret, H., Leverger, G., Ifrah, N., Hermine, O., Macintyre, E., Asnafi, V., Cytokines, hématopoïèse et réponse immune (CHRI), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Slama, Catherine, and Université Paris Descartes - Paris 5 (UPD5) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Centre National de la Recherche Scientifique (CNRS)

Subjects
ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2012

121. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias

Author

Porter, Jb, Lin, Kh, Beris, P, Forni, Gl, Taher, A, Habr, D, Domokos, G, Roubert, B, Thein, Sl, EPIC study investigators including Agaoglu, L, Alimena, G, Alonso, D, Ame, S, Angelucci, E, Arrizabalaga, B, Athanasiou Metaxa, M, Augustson, B, Aydinok, Y, Baba, A, Baccarani, M, Beck, J, Beyne Rauzy, O, Birgens, H, Bordessoule, D, Borgna Pignatti, C, Bosly, A, Bouabdallah, K, Bowen, D, Bron, D, Cappellini, Md, Capra, M, Cartron, G, Cazzola, M, Chalkias, C, Chan, Ll, Chancharunee, S, Chapman, C, Charoenkwan, P, Chasapopoulou, E, Cheze, S, Chuansumrit, A, Cianciulli, P, Dauriac, C, Delforge, M, Dölken, G, Dombret, H, Duyster, J, Economopoulos, T, Ehninger, G, Elalfy, M, El Beshlawy, A, Enggaard, L, Fenaux, P, Fillet, G, Filosa, A, Galanello, R, Ganser, A, Gastl, G, Gattermann, N, Giraudier, S, Goldfarb, A, Grigg, A, Guerci Bresler, A, Gumruk, F, Ha, Sy, Haase, D, Heinrich, B, Hertzberg, M, Ho, J, Hsu, Hc, Huang, S, Hunault Berger, M, Inusa, B, Jalumes, D, Jensen, J, Kattamis, A, Kilinc, Y, Kim, Kh, Kinsey, S, Kjeldsen, L, Koren, A, Lai, Me, Lai, Y, Lee, Jw, Lee, Kh, Lee, Sh, Legros, L, Li, C, Li, Ck, Li, Q, Linkesch, W, Lübbert, M, Lutz, D, Mohamed Thalha AJ, Mufti, G, Muus, P, Nobile, F, Ozsahin, H, Papadopoulos, N, Perrotta, S, Petrini, M, Pfeilstöcker, M, Piga, Antonio Giulio, Poole, J, Pungolino, E, Quarta, G, Ravoet, C, Remacha, Af, Rose, C, Roy, L, Saglio, Giuseppe, Sanz, G, Schmid, M, Schmugge, M, Schots, H, Secchi, G, Seymour, Jf, Shah, F, Shah, H, Shen, Z, Slama, B, Sutcharitchan, P, Tamary, H, Taylor, K, Tesch, Hj, Troncy, J, Vassilieff, D, Villegas, A, Viprakasit, V, Wainwright, L, Wassmann, B, Wettervald, M, Will, A, Wörmann, B, Wright, J, Yeh, Sp, Yoon, Ss, Zoumbos, Nc, Zweegman, S., Ozsahin, Ayse Hulya, Porter, Jb, Lin, Kh, Beris, P, Forni, Gl, Taher, A, Habr, D, Domokos, G, Roubert, B, Thein, Sl, on behalf of the EPIC study, Investigator, and Perrotta, Silverio

Subjects
safety, Male, Iron Overload, Adolescent, iron chelation therapy, Iron, Iron Chelating Agents/therapeutic use, Iron Chelating Agents, Benzoates, Anemia/drug therapy, Humans, Blood Transfusion, Benzoates/therapeutic use, Child, Iron/blood, ddc:616, ddc:618, iron overload, rare anaemias, serum ferritin, Ferritins/blood, Anemia, Original Articles, Triazoles, Deferasirox, Child, Preschool, Ferritins, rare anaemia, Female, Triazoles/therapeutic use
Abstract

Objectives: It is widely assumed that, at matched transfusional iron-loading rates, responses to chelation therapy are similar, irrespective of the underlying condition. However, data are limited for rare transfusiondependent anaemias, and it remains to be elucidated if response differs, depending on whether the anaemia has a primary haemolytic or production mechanism. Methods: The efficacy and safety of deferasirox (Exjade) in rare transfusion-dependent anaemias were evaluated over 1 yr, with change in serum ferritin as the primary efficacy endpoint. Initial deferasirox doses were 10–30 mg⁄ kg ⁄ d, depending on transfusion requirements; 34 patients had production anaemias, and 23 had haemolytic anaemias. Results: Patients with production anaemias or haemolytic anaemias had comparable transfusional iron-loading rates (0.31 vs. 0.30 mL red blood cells ⁄ kg ⁄ d), mean deferasirox dosing (19.3 vs. 19.0 mg⁄ kg ⁄ d) and baseline median serum ferritin (2926 vs. 2682 ng ⁄ mL). Baseline labile plasma iron (LPI) levels correlated significantly with the transfusional iron-loading rates and with serum ferritin levels in both cohorts. Reductions in median serum ferritin levels were initially faster in the production than the haemolytic anaemias, but at 1 yr, similar significant reductions of 940 and 617 ng ⁄mL were attained, respectively ()26.0% overall). Mean LPI decreased significantly in patients with production (P < 0.0001) and haemolytic (P = 0.037) anaemias after the first dose and was maintained at normal mean levels (

Published
2011

122. The European LeukemiaNet: achievements and perspectives

Author

Hehlmann, R., Grimwade, D., Simonsson, B., Apperley, J., Baccarani, M., Barbui, T., Barosi, G., Bassan, R., Bene, M. C., Berger, U., Buchner, T., Burnett, A., Cross, N. C. P., De Witte, T. J. M., Dohner, H., Dombret, H., Einsele, H., Engelich, G., Foa, Roberto, Fonatsch, C., Gokbuget, N., Gluckman, E., Gratwohl, A., Guilhot, F., Haferlach, C., Haferlach, T., Hallek, M., Hasford, J., Hochhaus, A., Hoelzer, D., Kiladjian, J. J., Labar, B., Ljungman, P., Mansmann, U., Niederwieser, D., Ossenkoppele, G., Ribera, J. M., Rieder, H., Serve, H., Schrotz King, P., Sanz, M. A., Sauele, S., European Leukemianet For The, Hematology, and CCA - Innovative therapy

Subjects
Gerontology, Economic growth, Biomedical Research, Cooperative research, International Cooperation, Chronic lymphocytic leukemia, Medical Oncology, cooperative leukemia research, cure of leukemia, european leukemianet, leukemia management guidelines, transnational and interdisciplinary cooperation on leukemia, Special Article, European LeukemiaNet, hemic and lymphatic diseases, medicine, Humans, Competence (human resources), Societies, Medical, Leukemia, business.industry, Myelodysplastic syndromes, Translational research Immune Regulation [ONCOL 3], Myeloid leukemia, Hematology, medicine.disease, Minimal residual disease, Europe, european leukemia net, perspectives, business
Abstract

Contains fulltext : 96402.pdf (Publisher’s version ) (Open Access) The only way to cure leukemia is by cooperative research. To optimize research, the European LeukemiaNet integrates 105 national leukemia trial groups and networks, 105 interdisciplinary partner groups and about 1,000 leukemia specialists from 175 institutions. They care for tens of thousands of leukemia patients in 33 countries across Europe. Their ultimate goal is to cure leukemia. Since its inception in 2002, the European LeukemiaNet has steadily expanded and has unified leukemia research across Europe. The European LeukemiaNet grew from two major roots: 1) the German Competence Network on Acute and Chronic Leukemias; and 2) the collaboration of European Investigators on Chronic Myeloid Leukemia. The European LeukemiaNet has improved leukemia research and management across Europe. Its concept has led to funding by the European Commission as a network of excellence. Other sources (European Science Foundation; European LeukemiaNet-Foundation) will take over when the support of the European Commission ends.

Published
2011
Full Text
View/download PDF

124. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

Author

Lee, Jw, Yoon, Ss, Shen, Zx, Ganser, A, Hsu, Hc, Habr, D, Domokos, G, Roubert, B, Porter, Jb, Agaoglu, L, Alimena, G, Alonso, D, Ame, S, Angelucci, E, Arrizabalaga, B, Athanasiou Metaxa, M, Augustson, B, Aydinok, Y, Baba, A, Baccarani, M, Beck, J, Beris, P, Beyne Rauzy, O, Birgens, H, Bordessoule, D, Borgna, Caterina, Bosly, A, Bouabdallah, K, Bowden, D, Bowen, D, Bron, D, Cappellini, Md, Capra, M, Cartron, G, Cazzola, M, Chalkias, C, Chan, Ll, Chancharunee, S, Chapman, C, Charoenkwan, P, Chasapopoulou, E, Cheze, S, Chuansumrit, A, Cianciulli, P, Dauriac, C, Delforge, M, Dölken, G, Dombret, H, Duyster, J, Economopoulos, T, Ehninger, G, Elalfy, M, El Beshlawy, A, Enggaard, L, Fenaux, P, Fillet, G, Filosa, A, Forni, G, Galanello, R, Gastl, G, Gattermann, N, Giraudier, S, Goldfarb, A, Grigg, A, Guerci Bresler, A, Gumruk, F, Ha, Sy, Haase, D, Heinrich, B, Hertzberg, M, Ho, J, Huang, S, Hunault Berger, M, Inusa, B, Jaulmes, D, Jensen, J, Kattamis, A, Kilinc, Y, Kim, Kh, Kinsey, S, Kjeldsen, L, Koren, A, Lai, Me, Lai, Y, Lee, Kh, Lee, Sh, Legros, L, Li, C, Li, Ck, Li, Q, Lin, Kh, Linkesch, W, Lübbert, M, Lutz, D, Mohamed Thalha AJ, Mufti, G, Muus, P, Nobile, F, Papadopoulos, N, Perrotta, S, Petrini, M, Pfeilstöcker, M, Piga, A, Poole, J, Pungolino, E, Quarta, G, Ravoet, C, Remacha, Af, Rose, C, Roy, L, Saglio, G, Sanz, G, Schmid, M, Schmugge, M, Schots, H, Secchi, G, Seymour, Jf, Shah, F, Shah, H, Shen, Z, Slama, B, Sutcharitchan, P, Taher, A, Tamary, H, Taylor, K, Tesch, Hj, Thein, Sl, Troncy, J, Vassilieff, D, Villegas, A, Viprakasit, V, Wainwright, L, Wassmann, B, Wettervald, M, Will, A, Wörmann, B, Wright, J, Yeh, Sp, Zoumbos, Nc, Zweegman, S., Lee, Jw, Yoon, S, Shen, Zx, Ganser, A, Hsu, Hc, Habr, D, Domokos, G, Roubert, B, Porter, Jb, EPIC study, Investigator, and Perrotta, Silverio

Subjects
Male, Biochemistry, Gastroenterology, Benzoates, beta-thalassemia, chemistry.chemical_compound, overloaded patients, oxidative stress, Prospective Studies, Prospective cohort study, pathophysiology, Beta thalassemia, complications, epidemiology, labile plasma iron, myelodysplastic syndromes, serum ferritin, transfusion-dependent anemias, Anemia, Aplastic, Hematology, Middle Aged, Tolerability, Creatinine, Iron chelation, Female, medicine.drug, Adult, medicine.medical_specialty, aplastic anemia, Adolescent, Anemia, Immunology, Iron Chelating Agents, Young Adult, Internal medicine, medicine, Humans, Aplastic anemia, therapy, business.industry, Myelodysplastic syndromes, Deferasirox, deferasirox, Cell Biology, Triazoles, medicine.disease, Chelation Therapy, Surgery, chemistry, Ferritins, business
Abstract

The prospective 1-year Evaluation of Patients' Iron Chelation with Exjade (EPIC) study enrolled a large cohort of 116 patients with aplastic anemia; the present analyses evaluated the efficacy and safety of deferasirox in this patient population. After 1 year, median serum ferritin decreased significantly from 3254 ng/mL at baseline to 1854 ng/mL (P < .001). Decreases occurred in chelation-naive (3229-1520 ng/mL; P < .001, last-observation-carried-forward analysis), and previously chelated (3263-2585 ng/mL; P = .21, last-observation-carried-forward analysis) patients and were reflective of dose adjustments and ongoing iron intake. Baseline labile plasma iron levels were within normal range despite high serum ferritin levels. The most common drug-related adverse events were nausea (22%) and diarrhea (16%). Serum creatinine increases more than 33% above baseline and the upper limit of normal occurred in 29 patients (25%), but there were no progressive increases; concomitant use of cyclosporine had a significant impact on serum creatinine levels. The decrease in mean alanine aminotransferase levels at 1 year correlated significantly with reduction in serum ferritin (r = 0.40, P < .001). Mean absolute neutrophil and platelet counts remained stable during treatment, and there were no drug-related cytopenias. This prospective dataset confirms the efficacy and well characterizes the tolerability profile of deferasirox in a large population of patients with aplastic anemia. This study was registered at www.clinicaltrials.gov as #NCT00171821.

Published
2010

125. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

Author

Borthakur, G., primary, Dombret, H., additional, Schafhausen, P., additional, Brummendorf, T. H., additional, Boissel, N., additional, Jabbour, E., additional, Mariani, M., additional, Capolongo, L., additional, Carpinelli, P., additional, Davite, C., additional, Kantarjian, H., additional, and Cortes, J. E., additional

Published
2015
Full Text
View/download PDF

126. 15 HLA-MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION IMPROVES OVERALL SURVIVAL OF HIGHER RISK MYELODYSPLASTIC SYNDROME

Author

Robin, M., primary, Porcher, R., additional, Ades, L., additional, Raffoux, E., additional, Michallet, M., additional, François, S., additional, Cahn, J.Y., additional, Delmer, A., additional, Wattel, E., additional, Vigouroux, S., additional, Bay, J.O., additional, Cornillon, J., additional, Huynh, A., additional, Nguyen, S., additional, Rubio, M.T., additional, Vincent, L., additional, Maillard, N., additional, Charbonnier, A., additional, de Latour, R. Peffault, additional, Oumedaly, R., additional, Dombret, H., additional, Fenaux, P., additional, and Socié, G., additional

Published
2015
Full Text
View/download PDF

127. 50 BCL2L10-POSITIVE CELL (BPC) QUANTIFICATION IS A PREDICTIVE FACTOR OF SURVIVAL IN AZA-TREATED HIGHER RISK MDS (HR-MDS) AND AML

Author

Cluzeau, T., primary, Vidal, V., additional, Ginet, C., additional, Karsenti, J.M., additional, Luciano, F., additional, Gastaud, L., additional, Garnier, G., additional, Braun, T., additional, Hirsch, P., additional, Raffoux, E., additional, Nloga, A.M., additional, Dombret, H., additional, Rorhlich, P., additional, Ades, L., additional, Chomienne, C., additional, Auberger, P., additional, Robert, G., additional, and Fenaux, P., additional

Published
2015
Full Text
View/download PDF

128. 124 AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML (>30% MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: SUBGROUP ANALYSIS OF THE AZA-AML-001 STUDY

Author

Seymour, J.F., primary, Döhner, H., additional, Butrym, A., additional, Wierzbowska, A., additional, Selleslag, D., additional, Jang, J.H., additional, Cavenagh, J.D., additional, Kumar, R., additional, Schuh, A.C., additional, Candoni, A., additional, Récher, C., additional, Sandhu, I., additional, del Castillo, T. Bernal, additional, Al-Ali, H.K., additional, Martinelli, G., additional, Falantes, J., additional, Nopenney, R., additional, Stone, R.M., additional, Minden, M.D., additional, McIntyre, H., additional, Songer, S., additional, Lucy, L.M., additional, Beach, C.L., additional, and Dombret, H., additional

Published
2015
Full Text
View/download PDF

129. 96 OVERALL SURVIVAL IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML WITH >30% BONE MARROW BLASTS AND POOR-RISK CYTOGENETICS TREATED WITH AZACITIDINE: SUBANALYSIS OF THE AZA-AML-001 STUDY

Author

Döhner, H., primary, Seymour, J.F., additional, Butrym, A., additional, Wierzbowska, A., additional, Selleslag, D., additional, Jang, J.H., additional, Cavenagh, J.D., additional, Kumar, R., additional, Schuh, A.C., additional, Candoni, A., additional, Récher, C., additional, Sandhu, I., additional, del Castillo, T. Bernal, additional, Al-Ali, H.K., additional, Martinelli, G., additional, Falantes, J., additional, Nopenney, R., additional, Stone, R.M., additional, Minden, M.D., additional, McIntyre, H., additional, Songer, S., additional, Lucy, L.M., additional, Beach, C.L., additional, and Dombret, H., additional

Published
2015
Full Text
View/download PDF

133. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Author

Gattermann, N., Finelli, C., Porta, M. D., Fenaux, P., Ganser, A., Guerci Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., Domokos, G., Roubert, B., Rose, C., Agaoglu, L., Alimena, G., Alonso, D., Ame, S., Angelucci, E., Businco, A., Arrizabalaga, B., Athanasiou Metaxa, M., Augustson, B., Aydinok, Y., Baba, A., Baccarani, M., Beck, J., Beris, P., Beyne Rauzy, O., Birgens, H., Bordessoule, D., Borgna, Caterina, Bosly, A., Bouabdallah, K., Bowden, D., Bowen, D., Bron, D., Cappellini, M. D., Capra, M., Cartron, G., Cazzola, M., Chalkias, C., Chan, L. L., Chancharunee, S., Chapman, C., Charoenkwan, P., Chasapopoulou, E., Cheze, S., Chuansumrit, A., Cianciulli, P., Dauriac, C., Delforge, M., Dölken, G., Dombret, H., Duyster, J., Economopoulos, T., Ehninger, G., Elalfy, M., El Beshlawy, A., Enggaard, L., Fillet, G., Filosa, A., Forni, G., Galanello, R., Gastl, G., Giraudier, S., Goldfarb, A., Grigg, A., Gumruk, F., S. Y., Ha, Haase, D., Heinrich, B., Hertzberg, M., Ho, J., Hsu, H. C., Huang, S., Hunault Berger, M., Inusa, B., Jaulmes, D., Jensen, J., Kattamis, A., Kilinc, Y., Kim, K. H., Kinsey, S., Kjeldsen, L., Koren, A., Lai, M. E., Lai, Y., Lee, J. W., Lee, K. H., Lee, S. H., Legros, L., Li, C., C. K., Li, Li, Q., Lin, K. H., Linkesch, W., Lübbert, M., Lutz, D., Mohamed Thalha, A. J., Mufti, G., Muus, P., Nobile, F., Papadopoulos, N., Perrotta, S., Petrini, M., Pfeilstöcker, M., Piga, A., Poole, J., Porter, J. B., Pungolino, E., Quarta, G., Ravoet, C., Jolimont Lobbes, H. H., Remacha, A. F., Roy, L., Saglio, G., Sanz, G., Schmugge, M., Schots, H., Secchi, G., Seymour, J. F., Shah, F., Shah, H., Shen, Z., Slama, B., Sutcharitchan, P., Taher, A., Tamary, H., Tesch, H. J., Thein, S. L., Troncy, J., Villegas, A., Viprakasit, V., Wainwright, L., Wassmann, B., Wettervald, M., Will, A., Wörmann, B., Wright, J., Yeh, S. P., Yoon, S. S., Zoumbos, N. S., Zweegman, S., Gattermann, N, Finelli, C, Porta, Md, Fenaux, P, Ganser, A, GUERCI BRESLER, A, Schmid, M, Taylor, K, Vassilieff, D, Habr, D, Domokos, G, Roubert, B, Rose, C, EPIC study, Investigator, Perrotta, Silverio, Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C, Baccarani M, EPIC study investigators., and Çukurova Üniversitesi

Subjects
Male, Pediatrics, Cancer Research, Blood transfusion, Thalassemia, medicine.medical_treatment, Gastroenterology, Benzoates, Child, Hematology, biology, Benzoic Acids, Alanine Transaminase, Adolescent, Adult, Aged, Blood Transfusion, Preschool, Female, Ferritins, Humans, Iron Chelating Agents, Iron Overload, Middle Aged, Myelodysplastic Syndromes, Triazoles, Young Adult, Oncology, Child, Preschool, medicine.drug, medicine.medical_specialty, Myelodysplastic syndromes, deferasirox, iron chelation therapy, labile plasma iron, myelodysplastic syndromes, serum ferritin, Serum ferritin, Deferasirox, Iron chelation therapy, Labile plasma iron, Internal medicine, medicine, Adverse effect, iron-overloaded patients, transfusion, Labile plasmairon, business.industry, medicine.disease, Discontinuation, Iron chelationtherapy, Alanine transaminase, biology.protein, business, Myelodysplastic syndrome
Abstract

PubMedID: 20451251 The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ~50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p

Published
2010

134. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Author

Gattermann, N. Finelli, C. Della Porta, M. Fenaux, P. Ganser, A. Guerci-Bresler, A. Schmid, M. Taylor, K. Vassilieff, D. Habr, D. Domokos, G. Roubert, B. Rose, C. Agaoglu, L. Alimena, G. Alonso, D. Ame, S. Angelucci, E. Arrizabalaga, B. Athanasiou-Metaxa, M. Augustson, B. Aydinok, Y. Baba, A. Baccarani, M. Beck, J. Beris, P. Beyne-Rauzy, O. Birgens, H. Bordessoule, D. Borgna-Pignatti, C. Bosly, A. Bouabdallah, K. Bowden, D. Bowen, D. Bron, D. Cappellini, M.D. Capra, M. Cartron, G. Cazzola, M. Chalkias, C. Chan, L.L. Chancharunee, S. Chapman, C. Charoenkwan, P. Chasapopoulou, E. Cheze, S. Chuansumrit, A. Cianciulli, P. Dauriac, C. Delforge, M. Dölken, G. Dombret, H. Duyster, J. Economopoulos, T. Ehninger, G. Elalfy, M. El-Beshlawy, A. Enggaard, L. Fillet, G. Filosa, A. Forni, G. Galanello, R. Gastl, G. Giraudier, S. Goldfarb, A. Grigg, A. Gumruk, F. Ha, S.Y. Haase, D. Heinrich, B. Hertzberg, M. Ho, J. Hsu, H.-C. Huang, S. Hunault-Berger, M. Inusa, B. Jaulmes, D. Jensen, J. Kattamis, A. Kilinc, Y. Kim, K.-H. Kinsey, S. Kjeldsen, L. Koren, A. Lai, M.E. Lai, Y. Lee, J.-W. Lee, K.-H. Lee, S.-H. Legros, L. Li, C. Li, C.-K. Li, Q. Lin, K.-H. Linkesch, W. Lübbert, M. Lutz, D. Mohamed Thalha, A.J. Mufti, G. Muus, P. Nobile, F. Papadopoulos, N. Perrotta, S. Petrini, M. Pfeilstöcker, M. Piga, A. Poole, J. Porter, J.B. Pungolino, E. Quarta, G. Ravoet, C. Jolimont Lobbes, H.H. Remacha, A.F. Roy, L. Saglio, G. Sanz, G. Schmugge, M. Schots, H. Secchi, G. Seymour, J.F. Shah, F. Shah, H. Shen, Z. Slama, B. Sutcharitchan, P. Taher, A. Tamary, H. Tesch, H.-J. Thein, S.L. Troncy, J. Villegas, A. Viprakasit, V. Wainwright, L. Wassmann, B. Wettervald, M. Will, A. Wörmann, B. Wright, J. Yeh, S.-P. Yoon, S.-S. Zoumbos, N.C. Zweegman, S.

Abstract

The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p

Published
2010

135. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Author

Dohner, H, Estey, EH, Amadori, S, Appelbaum, FR, Buchner, T, Burnett, AK, Dombret, H, Fenaux, P, Grimwade, D, Larson, RA, Lo-Coco, F, Naoe, T, Niederwieser, D, Ossenkoppele, GJ, Sanz, MA, Sierra, J, Tallman, MS, Lowenberg, B, and Bloomfield, CD

Abstract

In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed. (Blood. 2010; 115: 453-474)

Published
2010

136. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia

Author

Callens, C., Coulon, S., Radford-Weiss, I., Boissel, N., Raffoux, E., Wang P. Huey, Mei, Asnafi, V., Dessen, P., Canioni, D., Chandesris, O., Rubio, M.T., Benhamou, M., Dombret, H., Macintyre, E., Monteiro, R.C., Moura, I.C., Hermine, O., Cytokines, hématopoïèse et réponse immune (CHRI), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Pathologie et virologie moléculaire (PVM (UMR_7151)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Génomes et cancer (GC (FRE2939)), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Génétique Oncologique, Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physique des Polymères et Phénomènes Critiques [Casablanca] (LPPPC), Faculté des Sciences Ben M'sik [Casablanca], Université Hassan II [Casablanca] (UH2MC)-Université Hassan II [Casablanca] (UH2MC), Cytokines, hématopoïèse et réponse immune ( CHRI ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Pathologie et virologie moléculaire ( PVM ), Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ), Génomes et cancer ( GC (FRE2939) ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut Gustave Roussy ( IGR ) -Centre National de la Recherche Scientifique ( CNRS ), Institut Gustave Roussy ( IGR ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de Physique des Polymères et Phénomènes Critiques ( LPPPC ), Faculté des Sciences Ben M'Sik, Pathologie et virologie moléculaire (PVM), and Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)

Subjects
ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2010

137. JAK1 mutations are not frequent events in adult T-ALL: A GRAALL study

Author

Asnafi, V., Noir S., Le, Lhermitte, L., Gardin, C., Legrand, F., Vallantin, X., Malfuson, J.-V., Ifrah, N., Dombret, H., Macintyre, E., Cytokines, hématopoïèse et réponse immune (CHRI), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz, Université Paris Descartes - Paris 5 (UPD5) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon) - hopital Jean Minjoz

Subjects
ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2010

138. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

Author

Cappellini, M. D., Porter, J., El Beshlawy, A., C. K., Li, Seymour, J. F., Elalfy, M., Gattermann, N., Giraudier, S., Lee, J. W., Chan, L. L., Lin, K. H., Rose, C., Taher, A., Thein, S. L., Viprakasit, V., Habr, D., Domokos, G., Roubert, B., Kattamis, A., Agaoglu, L., Alimena, G., Alonso, D., Ame, S., Angelucci, E., Businco, A., Arrizabalaga, B., Athanasiou Metaxa, M., Augustson, B., Aydinok, Y., Baba, A., Baccarani, M., Beck, J., Beris, P., Beyne Rauzy, O., Birgens, H., Bordessoule, D., Borgna, Caterina, Bosly, A., Bouabdallah, K., Bowden, D., Bowen, D., Bron, D., Capra, M., Cartron, G., Cazzola, M., Chalkias, C., Chancharunee, S., Chapman, C., Charoenkwan, P., Chasapopoulou, E., Cheze, S., Chuansumrit, A., Cianciulli, P., Dauriac, C., Delforge, M., Dölken, G., Dombret, H., Duyster, J., Economopoulos, T., Ehninger, G., Enggaard, L., Fillet, G., Filosa, A., Forni, G., Galanello, R., Gastl, G., Goldfarb, A., Grigg, A., Gumruk, F., S. Y., Ha, Haase, D., Heinrich, B., Hertzberg, M., Ho, J., Hsu, H. C., Huang, S., Hunault Berger, M., Inusa, B., Jaulmes, D., Jensen, J., Kilinc, Y., Kim, K. H., Kinsey, S., Kjeldsen, L., Koren, A., Lai, M. E., Lai, Y., Lee, K. H., Lee, S. H., Legros, L., Li, C., Li, Q., Linkesch, W., Lübbert, M., Lutz, D., Mohamed Thalha, A. J., Mufti, G., Muus, P., Nobile, F., Papadopoulos, N., Perrotta, S., Petrini, M., Pfeilstöcker, M., Piga, A., Poole, J., Porter, J. B., Pungolino, E., Quarta, G., Ravoet, C., Jolimont Lobbes, H. H., Remacha, A. F., Roy, L., Saglio, G., Sanz, G., Schmugge, M., Schots, H., Secchi, G., Shah, F., Shah, H., Shen, Z., Slama, B., Sutcharitchan, P., Tamary, H., Tesch, H. J., Troncy, J., Villegas, A., Wainwright, L., Wassmann, B., Wettervald, M., Will, A., Wörmann, B., Wright, J., Yeh, S. P., Yoon, S. S., Zoumbos, N. S., and Zweegman, S.

Subjects
Adult, Male, medicine.medical_specialty, Pediatrics, Blood transfusion, Iron Overload, Adolescent, Anemia, Thalassemia, medicine.medical_treatment, Iron chelation therapy, Transfusion medicine, Transfusion-dependent anemias, Hemosiderosis, Iron Chelating Agents, Gastroenterology, Benzoates, Young Adult, IRON CHELATION, Internal medicine, medicine, Humans, Blood Transfusion, Tissue Distribution, SERUM FERRITIN, Chelation therapy, Prospective Studies, Child, Aged, Aged, 80 and over, business.industry, Myelodysplastic syndromes, Deferasirox, Hematology, Middle Aged, Triazoles, medicine.disease, DEFERASOROX, Deferoxamine, Child, Preschool, Ferritins, Female, Original Article, business, TRANSFUSION-DEPENDENT ANEMIAS, Iron, Dietary, medicine.drug
Abstract

Background Following a clinical evaluation of deferasirox (Exjade) it was concluded that, in addition to baseline body iron burden, ongoing transfusional iron intake should be considered when selecting doses. The 1-year EPIC study, the largest ever investigation conducted for an iron chelator, is the first to evaluate whether fixed starting doses of deferasirox, based on transfusional iron intake, with dose titration guided by serum ferritin trends and safety markers, provides clinically acceptable chelation in patients (agedor=2 years) with transfusional hemosiderosis from various types of anemia.The recommended initial dose was 20 mg/kg/day for patients receiving 2-4 packed red blood cell units/month and 10 or 30 mg/kg/day was recommended for patients receiving less or more frequent transfusions, respectively. Dose adjustments were based on 3-month serum ferritin trends and continuous assessment of safety markers. The primary efficacy end-point was change in serum ferritin after 52 weeks compared with baseline.The 1744 patients enrolled had the following conditions; thalassemia (n=1115), myelodysplastic syndromes (n=341), aplastic anemia (n=116), sickle cell disease (n=80), rare anemias (n=43) and other transfused anemias (n=49). Overall, there was a significant reduction in serum ferritin from baseline (-264 ng/mL; P0.0001), reflecting dosage adjustments and ongoing iron intake. The most common (5%) adverse events were gastrointestinal disturbances (28%) and skin rash (10%). Conclusions Analysis of this large, prospectively collected data set confirms the response to chelation therapy across various anemias, supporting initial deferasirox doses based on transfusional iron intake, with subsequent dose titration guided by trends in serum ferritin and safety markers (clinicaltrials.gov identifier: NCT00171821).

Published
2009

139. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Author

Fenaux, P, Mufti, Gj, Hellstrom Lindberg, E, Santini, V, Finelli, C, Giagounidis, A, Schoch, R, Gattermann, N, Sanz, G, List, A, Gore, Sd, Seymour, Jf, Bennett, Jm, Byrd, J, Backstrom, J, Zimmerman, L, Mckenzie, D, Beach, C, Silverman, Lr, Durrant, S, Enno, A, Herrmann, R, Horvath, N, Mills, A, Spencer, A, Szer, J, Gallo, J, Dunlop, L, Arthur, C, Goranov, S, Peytchev, D, Gercheva, L, Cermak, J, Voglova, J, Vey, N, Dreyfus, F, Laurent, G, Quesnel, B, Dombret, H, Stamatoullas, A, Wattel, E, Hunault Berger, M, Aul, C, Duhrsen, U, Platzbecker, U, Schmid, M, Hanel, M, Haase, D, Fiedler, W, Schmitz, N, Hofmann, W, Horst, H, Anagnostopoulos, N, Pappa, V, Papadaki, E, Zoumbos, N, Borbenyi, Z, Masszi, T, Baccarani, M, Bacigalupo, A, Corradini, P, Leone, G, Sacchi, Stefano, Bosi, A, Musto, P, Muus, P, Dmoszynska, A, Robak, T, Sulek, K, Kuliczkowski, K, Jedrzejczak, W, Zaritsky, A, Abdulkadyrov, K, Podoltseva, E, Afanasiev, B, Bargay, J, Brunet, S, Del Canizo, C, Ribera, J, Figuera Alvarez, A, Diaz Mediavilla, J, Canales, M, Ortega F, Ramos y., Nilsson, L, Olsson, A, Cavenagh, J, Parker, J, Killick, S, Kruger, A, Vyas, P, Dennis, M, Cripe, L, Dipersio, J, and Emanuel, P.

Subjects
Adult, Male, medicine.medical_specialty, azacitidine, Antimetabolites, Antineoplastic, Azacitidine, Decitabine, Article, law.invention, Randomized controlled trial, law, Internal medicine, medicine, Clinical endpoint, Humans, Intensive care medicine, Aged, Proportional Hazards Models, Aged, 80 and over, Intention-to-treat analysis, business.industry, Hazard ratio, Middle Aged, Oncology, Hypomethylating agent, International Prognostic Scoring System, Myelodysplastic Syndromes, Female, business, medicine.drug
Abstract

Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens.In a phase III, international, multicentre, controlled, parallel-group, open-label trial, patients with higher-risk myelodysplastic syndromes were randomly assigned one-to-one to receive azacitidine (75 mg/m(2) per day for 7 days every 28 days) or conventional care (best supportive care, low-dose cytarabine, or intensive chemotherapy as selected by investigators before randomisation). Patients were stratified by French-American-British and international prognostic scoring system classifications; randomisation was done with a block size of four. The primary endpoint was overall survival. Efficacy analyses were by intention to treat for all patients assigned to receive treatment. This study is registered with ClinicalTrials.gov, number NCT00071799.Between Feb 13, 2004, and Aug 7, 2006, 358 patients were randomly assigned to receive azacitidine (n=179) or conventional care regimens (n=179). Four patients in the azacitidine and 14 in the conventional care groups received no study drugs but were included in the intention-to-treat efficacy analysis. After a median follow-up of 21.1 months (IQR 15.1-26.9), median overall survival was 24.5 months (9.9-not reached) for the azacitidine group versus 15.0 months (5.6-24.1) for the conventional care group (hazard ratio 0.58; 95% CI 0.43-0.77; stratified log-rank p=0.0001). At last follow-up, 82 patients in the azacitidine group had died compared with 113 in the conventional care group. At 2 years, on the basis of Kaplan-Meier estimates, 50.8% (95% CI 42.1-58.8) of patients in the azacitidine group were alive compared with 26.2% (18.7-34.3) in the conventional care group (p0.0001). Peripheral cytopenias were the most common grade 3-4 adverse events for all treatments.Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care.

Published
2009

140. 1040TiP - QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)

Author

Schlenk, R., Dombret, H., Amadori, S., Montesinos, P., Levis, M., Sekeres, M.A., Cortes, J., Perl, A., Zernovak, O., Mires, D., Ge, N., Zhang, H., Hanyok, J., Macintyre, S., Gökmen, S., Kobayashi, K., and Erba, H.

Published
2017
Full Text
View/download PDF

145. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia

Author

Ducastelle, S., Adès, L., Gardin, C., Dombret, H., Prébet, T., Eric DECONINCK, Rio, B., Thomas, X., Debotton, S., Guerci, A., Gratecos, N., Stamatoullas, A., Fegueux, N., Dreyfus, F., Fenaux, P., Wattel, E., Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hématologie clinique [Avicenne], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service Hématologie, Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'hématologie et oncologie médicale, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie-Université de Montpellier (UM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Virologie et pathogenèse virale (VPV), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Avicenne [AP-HP], Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Hôpital Lapeyronie-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, and Saas, Philippe

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Adult, Male, autologous stem cell transplantation, Adolescent, MESH: Survival Rate, Antineoplastic Agents, Transplantation, Autologous, Time, MESH: Transplantation, Homologous, Humans, Transplantation, Homologous, Aged, MESH: Adolescent, MESH: Aged, MESH: Humans, MESH: Middle Aged, MESH: Time, intensive chemotherapy, MESH: Adult, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, MESH: Follow-Up Studies, Middle Aged, MESH: Transplantation, Autologous, MESH: Male, myelodysplastic syndrome, Survival Rate, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, MESH: Antineoplastic Agents, Female, MESH: Stem Cell Transplantation, MESH: Leukemia, Myeloid, Acute, MESH: Myelodysplastic Syndromes, MESH: Female, Follow-Up Studies, Stem Cell Transplantation
Abstract

International audience; We report on the outcomes of 53 patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia secondary to MDS, autografted in first complete remission. Five (9.4%) died from the procedure whereas hematological reconstitution occurred in all the remaining patients. Forty patients (75%) relapsed, with 87.5% of the relapses occurring within 2 years of the autologous transplant. With a median follow-up of 6.2 years, the median actuarial disease-free survival and overall survival were 8 and 17 months after autograft, respectively. Karyotype was the only prognostic factor for disease-free and overall survival. The eight survivors (15%), including two patients with unfavorable or intermediate karyotype, remained in first complete remission 50+ to 119+ months after transplantation and are probably cured.

Published
2006

146. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial

Author

Boissel, N., primary, Renneville, A., additional, Leguay, T., additional, Lefebvre, P. C., additional, Recher, C., additional, Lecerf, T., additional, Delabesse, E., additional, Berthon, C., additional, Blanchet, O., additional, Prebet, T., additional, Pautas, C., additional, Chevallier, P., additional, Lepretre, S., additional, Girault, S., additional, Bonmati, C., additional, Guieze, R., additional, Himberlin, C., additional, Randriamalala, E., additional, Preudhomme, C., additional, Jourdan, E., additional, Dombret, H., additional, and Ifrah, N., additional

Published
2015
Full Text
View/download PDF

147. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Giebel, S., Labopin, M., Gorin, N.C., Caillot, D., Leguay, T., Schaap, N.P., Michallet, M., Dombret, H., Mohty, M., Giebel, S., Labopin, M., Gorin, N.C., Caillot, D., Leguay, T., Schaap, N.P., Michallet, M., Dombret, H., and Mohty, M.

Abstract

Contains fulltext : 138260.pdf (publisher's version ) (Closed access), BACKGROUND: Outcome of Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL) improved significantly with the introduction of tyrosine kinase inhibitors (TKIs). Autologous stem cell transplantation (ASCT) has never been considered a standard of care in this setting. The aim of our study was to analyse if results of ASCT improved in the era of TKIs. PATIENTS AND METHODS: One-hundred and seventy-seven adults with Ph+ ALL treated with ASCT in first complete remission were analysed for the impact of year of transplantation on outcome. Additional analysis was performed including 32 patients for whom detailed data on the use of TKIs and the status of minimal residual disease were collected. RESULTS: The probability of the overall survival (OS) at 3 years increased from 16% for transplants performed between 1996 and 2001 to 48% between 2002 and 2006 and 57% between 2007 and 2010 (P<.0001). Leukaemia-free survival (LFS) was 11%, 39% and 52%, respectively (P<.0001). Relapse incidence decreased from 70% to 45% and 45% (P=.01), respectively, while non-relapse mortality was 19%, 15% and 3% (P=.08). In a multivariate analysis, year of ASCT was the only independent factor influencing the risk of treatment failure (hazard ratio (HR)=0.37; P<.001). In a subgroup of 22 patients actually treated with TKIs and being in complete molecular remission at the time of ASCT, the LFS rate at 3 years was 65%. CONCLUSIONS: Results of ASCT for Ph+ ALL improved significantly over time. Prospective, innovative studies are needed to verify the role of ASCT in this patient setting.

Published
2014

148. Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia

Author

Peterlin, P., primary, Renneville, A., additional, Ben Abdelali, R., additional, Nibourel, O., additional, Thomas, X., additional, Pautas, C., additional, de Botton, S., additional, Raffoux, E., additional, Cayuela, J.-M., additional, Boissel, N., additional, Terre, C., additional, Celli-Lebras, K., additional, Castaigne, S., additional, Preudhomme, C., additional, Gardin, C., additional, and Dombret, H., additional

Published
2014
Full Text
View/download PDF

149. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study

Author

Chevallier, P., primary, Huguet, F., additional, Raffoux, E., additional, Etienne, A., additional, Leguay, T., additional, Isnard, F., additional, Robillard, N., additional, Guillaume, T., additional, Delaunay, J., additional, Charbonnier, A., additional, Pigneux, A., additional, Peterlin, P., additional, Bene, M. C., additional, Wegener, W. A., additional, Goldenberg, D. M., additional, and Dombret, H., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results